CN Mobile Logo

Search form


Prostate Cancer

Prostate Cancer

Androgen deprivation therapy (ADT), a mainstay of treatment for men with prostate cancer, may raise the risk of dementia, according to a new study.

Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases (liver and lung) fare better with the androgen receptor inhibitor enzalutamide than placebo, according to a new analysis from the phase III AFFIRM trial.

Men who have vasectomies do not have a higher risk of prostate cancer and are not more likely to die from the disease, according to a large, prospective study.

While survival at 10 years was nearly identical (close to 99%), a new study found that localized prostate cancer is more likely to metastasize in men receiving active surveillance compared with those who have surgery or radiation therapy.

A 66-year-old Caucasian man with a history of hypertension, hyperlipidemia, and rheumatoid arthritis was diagnosed with prostate cancer.

In this interview we review recent breast cancer screening guidelines from the ACS and USPSTF, and discuss the changing way that early-stage breast and prostate cancers are being treated.

PSA failure in men with localized, intermediate- or high-risk prostate cancer was associated with increased all-cause mortality in only those patients with no or minimal comorbidity.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.